Ahead of Oxford Global’s R&D Series Drug Discovery Summit on 26-27 May 2019 in Berlin, Germany, Oxford Global spoke to Torsten Hoffmann of Taros Chemicals about his work in Pharmaceutical R&D and the opportunities and challenges in Drug Discovery…
Press releases
Communication is key to success, this is also true for science
Stay updated with the most recent developments and activities at Taros by reading our press releases.
Read more
I3-STM dealt with a new, tailor-made immunotherapeutic approach using small antibody mimetics synthesized for the therapy of triple-negative breast cancer (TNBC), which is still insufficiently treated with the classic methods. These drugs consist of components that stimulate the immune system and…
Taros’ CEO invited to speak on the exclusive Podcast of the XPOMET© Medicinale in Berlin, 10 – 12 Oct 2019. In the light of Dimitrios presenation at the XPOMET© Medicinale, he was invited to give a pre-talk about his opinion on the transformation of the drug discovery process and his activities to contribute to that…
ZeCardio Therapeutics (ZeCardioTx), a pharma company focused on the discovery of cardiovascular drugs using the zebrafish model and a proprietary screening platform, ZeCardio®, selected Taros’ SVP Drug Discovery, Dr. Torsten Hoffmann, to join…
Starting from a recently identified endogenous inhibitor of vascular calcifications, Taros Drug Discovery scientists will be working in close collaboration with the Lead Discovery Center (LDC) in Dortmund and the Institute for…
Looks interesting?
As a leading contract research organization in discovery chemistry and custom synthesis, Taros provides comprehensive solutions to meet our clients’ needs from diverse branches and applications
Our experienced chemists practice a pragmatic culture and customer-centric approach in order to exceed project expectations and, despite challenges, bridge very narrow timelines. They are trained to consider economic, safety and ecological boundaries and conditions laid out for all stages of the project.
